(Q37737870)

22 August 2017

1 reference

title

Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? (English)

1 reference

22 August 2017

0 references

1 reference

Filip K Knop

1

1 reference

22 August 2017

publication date

27 April 2010

1 reference

American Journal of Physiology - Endocrinology and Metabolism

22 August 2017

published in

1 reference

22 August 2017

volume

299

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

E10-3

1 reference

Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Incretin and islet hormonal responses to fat and protein ingestion in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Gallstones and diabetes: a case-control study in a free-living population sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Incretin-based therapy of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Identification of a nuclear receptor for bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Identification of membrane-type receptor for bile acids (M-BAR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Bile acids: natural ligands for an orphan nuclear receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Glucose-sensing in glucagon-like peptide-1-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Glucose sensing in L cells: a primary cell study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

TGR5-mediated bile acid sensing controls glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Targeting bile-acid signalling for metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Reduced Incretin Effect in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00137.2010

10.1152/AJPENDO.00137.2010

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference